The first heart failure therapy management point-of-care device with multiplex and multimodal sensor

Introduction

CardioCap is the first ever multiplex and multimodal point-of-care (POC) device used for heart failure (HF) therapy management. With just a prick on the patient’s finger and a drop of blood, healthcare professionals can deduce the severity of the HF patients’ conditions through simultaneous detection of 4 blood biomarkers, namely potassium, sodium, creatinine, and NT-proBNP.

Functionality

With the comprehensive data generated by the 4 biomarkers, healthcare professionals can make prompt and informed decisions on the appropriate treatment. By optimizing the drug dosage or exploring other treatment options, they can prevent patients from entering acute decompensation events or experiencing adverse side effects, such as kidney failure.

Device Description

CardioCap is a handheld POC device that works with a drop of blood from the prick of a finger and is as user-friendly as a glucometer. It performs at the same standard as the gold benchmarks (i.e., The Stratus CS by Siemens, COBAS CARDIAC NTproBNP+ by Roche, and standard laboratory testing), but is used after patients are discharged from hospitals.

Continuum of Care

With CardioCap, continuum care for HF patients is made available after hospital discharge, at the patient's home, community care centres, neighbourhood clinics, and pharmacies.

Impact on Healthcare

• Re-hospitalisation rate and mortality rate is expected to be reduced by at least 30%.
• It helps to free up hospital capacity for other emergency cases that could not be prevented.

Alignment with Health Initiatives

This mission is aligned with the health inequality gap in the EU, with the World Economic Forum (WEF) stating that ill health accounts for 20% of total healthcare costs. In closing the health inequality gap, the WEF urged for health initiatives such as POC that enable people to receive the health services they need.